The first commercial sqid-X system sale to be
used to triage COVID-19 patients in New
York state
TORONTO, May 5, 2020 /CNW/ - SQI Diagnostics Inc.
(TSX-V: SQD; OTCQX: SQIDF), a life sciences and
diagnostics company that develops and commercializes proprietary
technologies and products for advanced microarray diagnostics
("SQI"), has completed the sale of a sqid-X™ system to the
University of Buffalo ("UB") for
the purpose of using SQI's RALI-Dx™ Inflammatory Response Panel.
This represents the first capital sale of an SQI system to be used
in the testing of COVID-19 patients.
The instrument will be housed at KSL Laboratories in
Buffalo, NY. KSL is a partner of
UB and is a part of the front-line effort against the pandemic in
the hard-hit state of New
York.
RALI-Dx, a panel run in less than one hour, is comprised of
several biomarkers indicative of acute lung injury. These markers
have been shown to give a clinician insight into whether a patient
can be treated and released for self-monitored home care, admitted
to a standard hospital unit, or is likely to develop severe
life-threatening symptoms requiring immediate intensive care unit
(ICU) admittance and advanced respiratory care measures. This
ability to objectively triage COVID-19 patients in less than one
hour is could be a diagnostics industry first.
The data from clinical studies currently being conducted by
SQI's Canadian and U.S. partners, which are expected to generate
useful data within the next few months, are intended to be used to
file for Emergency Use Authorization (EUA) from the FDA and its
Health Canada equivalent. If approved, this could represent the
first prognostic COVID-19 assay to be allowed to be put into
clinical use. There are more than 50 diagnostic tests for COVID-19
that have received an EUA designation from the FDA, however none of
those tests are prognostic in nature or have the ability to triage
patients' treatment pathway.
"We are proud and excited to be partnering with such a
prestigious institution that is working tirelessly on the front
line of the war against the disease," said Eric Brouwer, PhD interim CEO of SQI. "RALI-Dx
will not just be first-to-market, but will be best-in-market, and
SQI hopes to provide clinicians with this significant weapon to
assist in those efforts as soon as possible."
About SQI Diagnostics
SQI Diagnostics is the life sciences and diagnostics company
that develops and commercializes proprietary technologies and
products for advanced microarray diagnostics. The Company's
proprietary microarray tests and fully-automated systems are
designed to simplify protein and antibody testing workflow,
increase throughput, reduce costs and provide excellent data
quality. For more information, please visit
www.sqidiagnostics.com.
Sales and Marketing Contact:
Vice President, Global Commercial Operations
Russ Peloquin
913.484.9022
rpeloquin@sqidiagnostics.com
SQI Investor Relations Contact:
Interim Chief Executive
Officer
Eric Brouwer,
PhD
416.674.9500 ext.
242
ebrouwer@sqidiagnostics.com
View original
content:http://www.prnewswire.com/news-releases/sqi-diagnostics-completes-sale-of-sqid-xtm-diagnostic-system-to-university-of-buffalo-301052367.html
SOURCE SQI Diagnostics Inc.